Does Rallies show Form 4 insider transactions for TRDA?

Yes. Rallies tracks TRDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TRDA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.

TRDA (Entrada Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of May 21, 2026, TRDA trades at $6.18 with a market cap of $228.65M and a P/E ratio of -1.49. TRDA moved +6.73% today. Year to date, TRDA is -42.48%; over the trailing twelve months it is -26.70%. Its 52-week range spans $4.93 to $21.79. Analyst consensus is strong buy with an average price target of $19.50. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TRDA stock inside the company?

Recent TRDA insider activity includes Sethuraman Natarajan sold 25.91K, Dowden Nathan J sold 15.00K, WENTWORTH KORY JAMES sold 2.50K, Dowden Nathan J sold 11.89K, and WENTWORTH KORY JAMES sold 11.39K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TRDA Key Metrics

Key financial metrics for TRDA
Metric	Value
Price	$6.18
Market Cap	$228.65M
P/E Ratio	-1.49
EPS	$-3.99
Dividend Yield	0.00%
52-Week High	$21.79
52-Week Low	$4.93
Volume	1
Avg Volume	0
Revenue (TTM)	$5.74M
Net Income	$-166.12M
Gross Margin	0.00%

Recent TRDA Insider Trades

Sethuraman Natarajan sold 25.91K (~$398.81K) on May 4, 2026.
Dowden Nathan J sold 15.00K (~$229.95K) on May 4, 2026.
WENTWORTH KORY JAMES sold 2.50K (~$32.38K) on Apr 1, 2026.
Dowden Nathan J sold 11.89K (~$155.19K) on Mar 10, 2026.
WENTWORTH KORY JAMES sold 11.39K (~$148.22K) on Mar 10, 2026.

Latest TRDA News

Entradas shares plunge after DMD therapy misses primary efficacy endpoints — May 8, 2026
Entrada Therapeutics Secures $255M Runway to Q3 2027 After ELEVATE-44 Cohort 1 Success — May 7, 2026
Entrada Therapeutics to Release Multiple Ascending Dose Phase 1/2 Cohort 1 Duchenne Study Results May 7 — May 6, 2026
Entrada Advances ELEVATE-44-201 with 12 mg/kg Dose Recommendation, $296M Cash Runway — Feb 26, 2026
Entrada Therapeutics Projects Q4 EPS Loss $1.32, Revenues Plunge 96.6% — Feb 26, 2026

TRDA Analyst Consensus

8 analysts cover TRDA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.50.

Common questions about TRDA

Who is trading TRDA stock inside the company?: Recent TRDA insider activity includes Sethuraman Natarajan sold 25.91K, Dowden Nathan J sold 15.00K, WENTWORTH KORY JAMES sold 2.50K, Dowden Nathan J sold 11.89K, and WENTWORTH KORY JAMES sold 11.39K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TRDA?: Yes. Rallies tracks TRDA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TRDA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.